Latest Utilities News

Infinity Lithium Corporation has withdrawn from Spain’s PERTE VEC IIa capital funding program, opting to return nearly €20 million due to prolonged permitting and regulatory hurdles.

Synertec Corporation has been appointed to Sydney Water’s SCADA and Electrical Services Panel, granting access to a significant pipeline of water infrastructure projects valued at $245 million over five years. This appointment strengthens Synertec’s foothold across Australia’s major water utilities.

ITM Isotope Technologies Munich SE and Radiopharm Theranostics have entered a strategic supply agreement for the critical radioisotope Lutetium-177, underpinning Radiopharm’s clinical development of targeted cancer therapies.

Gentrack reported a solid 9.8% revenue increase to NZ$112 million in HY25, driven by recurring revenue growth and international expansion, while net profit after tax surged 34.7%. The company’s outlook remains optimistic as it targets FY25 revenue above NZ$230 million and deeper market penetration across Asia, Europe, and the Middle East.

Gentrack Group Limited reported a solid 9.8% revenue increase to NZ$112 million in the first half of FY25, powered by strong recurring revenue growth in utilities and a surge in its airports division, Veovo. Net profit after tax jumped 34.7%, supported by currency gains and a lower tax rate.

Gentrack Group Ltd reported a robust 9.8% revenue increase and a 34.7% jump in net profit for the first half of FY25, driven by strong recurring revenues and strategic global expansion.

Etherstack plc has reported its highest ever half-year cash receipts, surpassing US$7 million in the first half of FY2025, signaling strong momentum and a promising revenue outlook for the year.

Microba Life Sciences reveals preliminary data from over 4,600 MetaXplore GI Plus tests showing significant clinical findings in the majority of patients, with two-thirds reporting symptom improvements following test-guided care.

Caspin Resources has successfully completed the first tranche of a $2.1 million capital raise, issuing over 34 million shares to institutional and sophisticated investors. The company now awaits shareholder approval to complete the remaining funding, underpinning its exploration ambitions across three promising Australian projects.

Universal Biosensors reports solid growth in its wine testing segment and outlines plans for a capital raise alongside the upcoming AQUASCOUT water testing device launch.

Cleo Diagnostics has completed alpha testing of its ovarian cancer pre-surgical triage assay kits, confirming robust performance and differentiation between benign and malignant disease. The company now moves forward to assay optimisation and manufacturing scale-up, edging closer to FDA submission and commercial launch.

Universal Biosensors reports a 6% sales increase in Q1 2025, driven by strong growth in wine and veterinary biosensors, while preparing to launch its innovative water testing product later this year.